Skip to main content
. 2017 Oct 11;12(2):370–379. doi: 10.1177/1557988317734519

Figure 3.

Figure 3.

The odds ratio of marketed antidepressants (from Serretti & Chiesa, 2009) and amitriptyline for sexual dysfunction. Based on the eight randomized clinical trials in this study, the odds ratio was 1.5, which was higher than the bupropion, amineptine, nefazodone, agomelatine, and moclobemide but was much lower than most new generation antidepressants.